Bruker Corp

BRKR

Equity

ISIN US1167941087 / Valor 1635622

NASDAQ (2024-09-18)

USD 66.80+2.72%

Bruker Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Bruker Corp is a leading analytical instrumentation company that provides high-performance scientific instruments and analytical solutions for scientists to explore life and materials at molecular, cellular, and microscopic levels. With a focus on life science molecular research, applied and pharma applications, microscopy, nanoanalysis, industrial applications, cell biology, preclinical imaging, clinical phenomics, proteomics research, and clinical microbiology, Bruker collaborates closely with customers to drive innovation, productivity, and success. With over 8500 employees worldwide, Bruker is dedicated to developing state-of-the-art technologies and solutions to meet the evolving analytical needs of its customers across the globe.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Bruker Corp's revenues for the second quarter of 2024 were $800.7 million, marking a 17.4% increase compared to $681.9 million in the second quarter of 2023. This growth includes a 7.4% organic revenue increase year-over-year and an 18.5% constant-exchange rate (CER) revenue growth.

Earnings Per Share

In the second quarter of 2024, Bruker Corp reported GAAP diluted earnings per share (EPS) of $0.05, compared to $0.39 in the same quarter of the previous year. Non-GAAP diluted EPS for Q2 2024 was $0.52, reflecting a 4.0% increase from $0.50 in Q2 2023.

Operating Income

Bruker Corp's GAAP operating income for the second quarter of 2024 was $48.1 million, down from $86.2 million in Q2 2023. However, non-GAAP operating income was $110.7 million, a 6.3% increase from $104.1 million in the same period last year.

First Half Financials

For the first half of 2024, Bruker Corp's revenues were $1,522.4 million, an 11.4% increase from $1,367.2 million in the first half of 2023. The company saw a 4.5% organic revenue growth year-over-year and an 11.9% CER revenue growth during this period.

FY 2024 Outlook

Bruker Corp has updated its FY 2024 revenue guidance to $3.38-$3.44 billion, which includes the NanoString business. This implies a revenue growth of 14% to 16% year-over-year, with organic revenue growth expected to be between 5% and 7%.

Summarized from source with an LLMView Source

Key figures

2.75%1Y

-19.9%3Y

55.4%5Y

Performance

36.0%1Y

35.5%3Y

37.2%5Y

Volatility